A theoretical examination of the relative importance of evolution management and drug development for managing resistance

Proceedings of the Royal Society B: Biological Sciences

Volumn 281, Issue 1797, 2014, Pages

  McClure, Nathan S ^a   Day, Troy ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Chemotherapy; Drug resistance; Pharmaceuticals; Treatment strategies

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT;

DRUG DEVELOPMENT; DRUG RESISTANCE; EVOLUTION; THEORETICAL MODEL;

ANTI-BACTERIAL AGENTS; ANTIMALARIALS; BIOLOGICAL EVOLUTION; DRUG DISCOVERY; DRUG RESISTANCE; MODELS, THEORETICAL;

EID: 84908690682     PISSN: 09628452     EISSN: 14712954     Source Type: Journal    
DOI: 10.1098/rspb.2014.1861     Document Type: Article

References (48)

1. Zur Wiesch PA, Kouyos R, Engelstädter J, Regoes RR, Principles of drug-resistance evolution in 236–247. (doi:10.1016/S1473-3099(10)
2. Bonhoeffer S. 2011 Population biological infectious diseases. Lancet Infect. Dis. 11, 70264-4)
3. Coates A, Hu Y, Bax R, Page C. 2002 The future challenges facing the development of new antimicrobial drugs. Nat. Rev. Drug Discov. 1, 895-910. (doi:10.1038/nrd940)
4. Goldberg DE, Siliciano RF, Jacobs WR. 2012 Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. Cell 148, 1271-1283. (doi:10.1016/j.cell.2012.02.021)
5. WHO. 2012 The evolving threat of antimicrobial resistance: options for action. Geneva, Switzerland: World Health Organization.
6. Levy SB, Marshall B. 2004 Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10, S122-S129. (doi:10.1038/nm1145)
7. CDC. 2013 Antibiotic resistant threats in the United States, 2013. Atlanta, GA: U.S. Department of Health and Human Services Centers for Disease Control and Prevention.
8. WHO. 2001 WHO global strategy for containment of antimicrobial resistance. Geneva, Switzerland: World Health Organization.
9. Shetty P. 2012 Malaria—the numbers game. Nature 484, S14-S15. (doi:10.1038/484S14a)
10. Thayer AM. 2005 Fighting malaria. Chem. Eng. News 83, 69–82.
11. Hyde JE. 2005 Drug-resistant malaria. Trends Parasit. 21, 494–498. (doi:10.1016/j.pt.2005.08.020)
12. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. 2002 Epidemiology of drug-resistant malaria. Lancet Infect. Dis. 2, 209-218. (doi:10.1016/S1473-3099(02)00239-6)
13. Clatworthy AE, Pierson E, Hung DT. 2007 Targeting virulence: a new paradigm for antimicrobial therapy. Nat. Chem. Biol. 3, 541-548. (doi:10.1038/nchembio.2007.24)
14. Palumbi SR. 2001 Humans as the world’s greatest evolutionary force. Science 293, 1786–1790. (doi:10.1126/science.293.5536.1786)
15. Jacoby GA. 2009 History of drug-resistant microbes. In Antimicrobial drug resistance (ed. DL Mayers), pp. 3–7. New York, NY: Humana Press.
16. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. 2011 The challenge of new drug discovery for tuberculosis. Nature 469, 483–490. (doi:10.1038/nature09657)
17. Bathurst I, Hentschel C. 2006 Medicines for malaria venture: sustaining antimalarial drug development. Trends Parasit. 22, 301-307. (doi:10.1016/j.pt.2006.05.011)
18. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. 2004 Antimalarial drug discovery: efficacy models for compound screening. Nat. Rev. Drug Discov. 3, 509-520. (doi:10.1038/nrd1416)
19. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos B., Lindborg SR, Schacht AL. 2010. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov. 9, 203-214.
20. IDSA. 2004 Bad bugs, no drugs: as antibiotic R&D stagnates, a public health crisis brews. Alexandria, VA: Infectious Diseases Society of America.
21. May M. 2014 Time for teamwork. Nature 509, S4-S5. (doi:10.1038/509S4a)
22. WHO. 2010 Guidelines for the treatment of malaria, 2nd edn. Geneva, Switzerland: World Health Organization.
23. Owens Jr.RC. 2008 Antimicrobial stewardship: concepts and strategies in the 21st century. Diagn. Microbiol. Infect. Dis. 61, 110-128. (doi:10.1016/j.diagmicrobio.2008.02.012)
24. Geli P, Laxminarayan R, Dunne M, Smith DL. 2012 ‘One-size-fits-all’? Optimizing treatment duration for bacterial infections. PLoS ONE 7, e29838. (doi:10.1371/journal.pone.0029838)
25. Fischbach MA. 2011 Combination therapies for combating antimicrobial resistance. Curr. Opin. Microbiol. 14, 519-523. (doi:10.1016/j.mib.2011.08.003)
26. Boni MF, Smith DL, Laxminarayan R. 2008 Benefits of using multiple first-line therapies against malaria. Proc. Natl Acad. Sci. USA 105, 14216-14221. (doi:10.1073/pnas.0804628105)
27. Kanthor R. 2014 Detection drives defense. Nature 509, S14-S15. (doi:10.1038/509S14a)
28. Kouyos RD, Abel zur Wiesch P, Bonhoeffer S. 2011 On being the right size: the impact of population size and stochastic effects on the evolution of drug resistance in hospitals and the community. PLoS Pathog. 7, e1001334. (doi:10.1371/journal.ppat.1001334)
29. Hede K. 2014 An infectious arms race. Nature 509, S2-S3. (doi:10.1038/509S2a)
30. Livermore DM. 2009 Has the era of untreatable infections arrived? J. Antimicrob. Chemother. 64, i29-i36. (doi:10.1093/jac/dkp255)
31. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, Van Soolingen D, Jensen P, Bayona J. 2010 Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375, 1830-1843. (doi:10.1016/S0140-6736(10)60410-2)
32. Nordmann P, Cuzon G, Naas T. 2009 The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9, 228-236. (doi:10.1016/S1473-3099(09)70054-4)
33. Munos B. 2009 Lessons form 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959-968. (doi:10.1038/nrd2961)
34. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett J., Edwards J. 2008 The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 155-164. (doi:10.1086/524891)
35. Boucher HW, Talbot GH, Bradley JS, Edwards J., Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009 Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12. (doi:10.1086/595011)
36. Cully M. 2014 The politics of antibiotics. Nature 509, S16-S17. (doi:10.1038/509S16a)
37. WHO. 2010 Global report on antimalarial drug efficacy and drug resistance: 2000–2010. Geneva, Switzerland: World Health Organization.
38. Gardella F et al. 2008 Antimalarial drug use in general populations of tropical Africa. Malar. J. 7, 124. (doi:10.1186/1475-2875-7-124)
39. Clavel F, Hance AJ. 2004 HIV drug resistance. N. Engl. J. Med. 350, 1023-1035. (doi:10.1056/NEJMra025195)
40. Little SJ et al. 2002 Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347, 385-394. (doi:10.1056/NEJMoa013552)
41. Thompson MA et al. 2010 Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society–USA panel. JAMA 304, 321-333. (doi:10.1001/jama.2010.1004)
42. Dye C. 2012 National and international policies to mitigate disease threats. Phil. Trans. R. Soc. B 367, 2893-2900. (doi:10.1098/rstb.2011.0373)
43. Dye C, Williams BG, Espinal MA, Raviglione MC. 2002 Erasing the world’s slow stain: strategies to beat multidrug-resistant tuberculosis. Science 295, 2042-2046. (doi:10.1126/science.1063814)
44. Lawn SD et al. 2013 Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect. Dis. 13, 349-361. (doi:10.1016/S1473-3099(13)70008-2)
45. Ginsberg A. 2011 The TB Alliance: overcoming challenges to chart the future course of TB drug development. Future Med. Chem. 3, 1247–1252. (doi:10.4155/fmc.11.82)
46. Bonhoeffer S, Lipsitch M, Levin BR. 1997 Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl Acad. Sci. USA 94, 12 106–12 111. (doi:10.1073/pnas.94.22.12106)
47. Read AF, Day T, Huijben S. 2011 The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proc. Natl Acad. Sci. USA 108, 10871-10877. (doi:10.1073/pnas.1100299108)
48. Smith DL, Klein EY, Mckenzie FE, Laxminarayan R. 2010 Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty. Malar. J. 9, 217. (doi:10.1186/1475-2875-9-217)